Rationalisation of the purification process for a phage active pharmaceutical ingredient

被引:2
|
作者
Lapras, B. [1 ,2 ]
Marchand, C. [1 ,3 ]
Merienne, C. [1 ]
Medina, M. [3 ,4 ]
Kolenda, C. [3 ,4 ]
Laurent, F. [3 ]
Pirot, F. [1 ,2 ]
机构
[1] Hop Edouard Herriot, Hosp Civils Lyon, FRIPHARM, Pharm Dept, F-69437 Lyon, France
[2] Claude Bernard Lyon 1 Univ, CNRS, UMR 5305, Inst Biol & Chim Prot IBCP,French Natl Ctr Sci Res, F-69007 Lyon, France
[3] Croix Rousse Hosp, Hosp Civils Lyon, French Natl Reference Ctr Staphylococci, Bacteriol Dept, F-69317 Lyon, France
[4] Claude Bernard Lyon 1 Univ, CNRS, INSERM, UMR 5308,U1111,Ctr Int Rech Infectiol CIRI, F-69365 Lyon, France
关键词
Bacteriophages; Phage active pharmaceutical ingredient; Phage purification; Phage lysate impurities; Separation unit operations; Rationalisation of process development; AFFECTING ENDOTOXIN REMOVAL; VIRUS PURIFICATION; AQUEOUS-SOLUTIONS; BACTERIOPHAGE; THERAPY; RNA; ELECTROKINETICS; ULTRAFILTRATION; CHROMATOGRAPHY; AGGREGATION;
D O I
10.1016/j.ejpb.2024.114438
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The resurgence of phage therapy, once abandoned in the early 20th century in part due to issues related to the purification process and stability, is spurred by the global threat of antibiotic resistance. Engineering advances have enabled more precise separation unit operations, improving overall purification efficiency. The present review discusses the physicochemical properties of impurities commonly found in a phage lysate, e.g., contaminants, phage-related impurities, and propagation-related impurities. Differences in phages and bacterial impurities properties are leveraged to elaborate a four-step phage purification process: clarification, capture and concentration, subsequent purification and polishing. Ultimately, a framework for rationalising the development of a purification process is proposed, considering three operational characteristics, i.e., scalability, transferability to various phages and duration. This guide facilitates the preselection of a sequence of unit operations, which can then be confronted with the expected impurities to validate the theoretical capacity of the process to purify the phage lysate.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Microparticle Production of Active Pharmaceutical Ingredient Using Supercritical Antisolvent Process: A Case Study of Allopurinol
    Khudaida, Salal Hasan
    Wang, Wei-Kai
    Wu, Wei-Yi
    Su, Chie-Shaan
    CRYSTALS, 2022, 12 (07)
  • [32] Application of Mid-Infrared Spectroscopy to the Development and Transfer of a Manufacturing Process for an Active Pharmaceutical Ingredient
    Clegg, Ian M.
    Daly, Adrian M.
    Donnelly, Craig
    Hardy, Ruth
    Harris, Denise
    Jackman, Hayley
    Jones, Ricky
    Luan, Amy
    McAndrew, Douglas
    McGauley, Pat
    Pearce, John
    Scotney, Gemma
    Yeow, May-Ling
    APPLIED SPECTROSCOPY, 2012, 66 (05) : 574 - 579
  • [33] Syntheses of Cinacalcet: An Enantiopure Active Pharmaceutical Ingredient (API)
    Barniol-Xicota, Marta
    Leiva, Rosana
    Escolano, Carmen
    Vazquez, Santiago
    SYNTHESIS-STUTTGART, 2016, 48 (06): : 783 - 803
  • [34] Rethinking cleaning validation for active pharmaceutical ingredient manufacturing
    Hadziselimovic, Dijana
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [35] Physico-chemical characterization of an active pharmaceutical ingredient
    S. Pfeffer-Hennig
    P. Piechon
    M. Bellus
    C. Goldbronn
    E. Tedesco
    Journal of Thermal Analysis and Calorimetry, 2004, 77 : 663 - 679
  • [36] Toward the Sustainable Production of the Active Pharmaceutical Ingredient Metaraminol
    Labib, Mohamed
    Grabowski, Laura
    Bruesseler, Christian
    Kallscheuer, Nicolai
    Wachtendonk, Luisa
    Fuchs, Thomas
    Jupke, Andreas
    Wiechert, Wolfgang
    Marienhagen, Jan
    Rother, Doerte
    Noack, Stephan
    ACS SUSTAINABLE CHEMISTRY & ENGINEERING, 2022, 10 (16): : 5117 - 5128
  • [37] Efficient Screening of Coformers for Active Pharmaceutical Ingredient Cocrystallization
    Sugden, Isaac J.
    Braun, Doris E.
    Bowskill, David H.
    Adjiman, Claire S.
    Pantelides, Constantinos C.
    CRYSTAL GROWTH & DESIGN, 2022, 22 (07) : 4513 - 4527
  • [38] Polymorphism of benzylthiouracil, an active pharmaceutical ingredient against hyperthyroidism
    Rietveld, Ivo B.
    Allouchi, Hassan
    Barrio, Maria
    Ceolin, Rene
    Tamarit, Josep-Lluis
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 598
  • [39] Review of Intranasal Active Pharmaceutical Ingredient Delivery Systems
    Safarov, Ruslan
    Fedotova, Olga
    Uvarova, Anastasia
    Gordienko, Mariia
    Menshutina, Natalia
    PHARMACEUTICALS, 2024, 17 (09)
  • [40] Incorporation of acetaminophen as an active pharmaceutical ingredient into porous lactose
    Ebrahimi, Amirali
    Saffari, Morteza
    Dehghani, Fariba
    Langrish, Timothy
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 499 (1-2) : 217 - 227